Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy

Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Med
Hauptverfasser: Navari, Rudolph M., Rapoport, Bernardo L., Powers, Dan, Arora, Sujata, Clark‐Snow, Rebecca
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Clinical Cancer Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6051205/
https://ncbi.nlm.nih.gov/pubmed/29790666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1560
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge